The risk or severity of adverse effects can be increased when Paclitaxel is combined with Thalidomide. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Rasagiline. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Saracatinib. The risk or severity of adverse effects can be increased when Fenoldopam is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Crenolanib. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Phentolamine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Carvedilol. The risk or severity of adverse effects can be increased when Nitrendipine is combined with Paclitaxel. The metabolism of Paclitaxel can be decreased when combined with Voriconazole. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Eplerenone. The serum concentration of Paclitaxel can be increased when it is combined with Mifepristone. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Cobimetinib. The risk or severity of myelosuppression can be increased when Metamizole is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ponatinib. The serum concentration of Simvastatin can be increased when it is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tiomolibdate ion. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pamidronate. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gefitinib. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Temoporfin. Satraplatin may increase the myelosuppressive activities of Paclitaxel. Oxaliplatin may increase the myelosuppressive activities of Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sirolimus. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Panitumumab. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptozocin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bisoprolol. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vitamin A. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolate mofetil. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ethyl carbamate. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lonidamine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Canertinib. The risk or severity of adverse effects can be increased when Paclitaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Phenylacetic acid. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Trastuzumab emtansine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Chlorambucil. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ramipril. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nalidixic Acid. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Trabectedin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Rhodamine 6G. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pentostatin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Anagrelide. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Fleroxacin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomustine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Eprosartan. The therapeutic efficacy of INGN 225 can be decreased when used in combination with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Idarubicin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with 3,3'-diindolylmethane. The metabolism of Paclitaxel can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lurtotecan. The risk or severity of adverse effects can be increased when Amifostine is combined with Paclitaxel. The serum concentration of Ubidecarenone can be increased when it is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Semaxanib. The metabolism of Paclitaxel can be decreased when combined with Sildenafil. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Lomefloxacin. The metabolism of Paclitaxel can be decreased when combined with Ziprasidone. The metabolism of Paclitaxel can be decreased when combined with Dronedarone. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sotalol. The serum concentration of Silodosin can be increased when it is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pembrolizumab. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Imiquimod. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Sulforaphane. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Didox. The metabolism of Paclitaxel can be decreased when combined with Cobicistat. The serum concentration of Pitavastatin can be increased when it is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Altretamine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with 9-aminocamptothecin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Cabergoline. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Fulvestrant. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ixazomib. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vinblastine. The risk or severity of adverse effects can be increased when Iloprost is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Thymalfasin. Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Norfloxacin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Degarelix. The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Tioguanine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Fosinopril. The metabolism of Paclitaxel can be decreased when combined with Verapamil. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemcitabine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Carteolol. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Octreotide. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Patupilone. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nadolol. Paclitaxel may increase the orthostatic hypotensive activities of Levodopa. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Batimastat. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Remifentanil. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Anecortave. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Axitinib. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pefloxacin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Verteporfin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with KRN-7000. The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Cilnidipine is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Atenolol. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendroflumethiazide. The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel. The metabolism of Paclitaxel can be decreased when combined with Rosiglitazone. The serum concentration of Paclitaxel can be increased when it is combined with Netupitant. The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Gemifloxacin. The risk or severity of adverse effects can be increased when Nilvadipine is combined with Paclitaxel. The serum concentration of Paclitaxel can be increased when it is combined with Simeprevir. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Hypericin. The risk or severity of adverse effects can be increased when Lofexidine is combined with Paclitaxel. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Triptolide. The risk or severity of adverse effects can be increased when Levosimendan is combined with Paclitaxel. The metabolism of Paclitaxel can be decreased when combined with Erythromycin. The risk or severity of adverse effects can be increased when Imipramine is combined with Paclitaxel. The metabolism of Paclitaxel can be decreased when combined with Ketoconazole. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nimustine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Pramipexole. The serum concentration of Paclitaxel can be increased when it is combined with Osimertinib. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Propofol. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Buthionine Sulfoximine. Methylphenobarbital may increase the hypotensive activities of Paclitaxel. The metabolism of Paclitaxel can be decreased when combined with Fosamprenavir. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dapagliflozin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Ubenimex. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Levobunolol. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Hadacidin. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Rotigotine. The metabolism of Paclitaxel can be decreased when combined with Efavirenz. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Toremifene. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Vinflunine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Apaziquone. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nisoldipine. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Leflunomide. The serum concentration of Rilpivirine can be increased when it is combined with Paclitaxel. Oleandrin may decrease the cardiotoxic activities of Paclitaxel.